Vice President, Medical Affairs

Company Overview

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by overcoming resistance in cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers.

Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to , and follow us on X or Linked In.

ORIC is seeking a Vice President, Medical Affairs, as an initial member of the Global Medical Affairs (GMA) team based in the South San Francisco office. Reporting to the SVP of Medical Affairs and Commercial, this senior leader will be responsible for developing and executing the US and global GMA strategy and tactical plans with a focus on launch readiness and life cycle management for therapies across prostate cancer, non‑small cell lung cancer (NSCLC), and potentially other tumor types.

The VP will build and scale a high‑performing GMA team while focusing on effectively analyzing and communicating key scientific data through publications, medical information, medical communications, and congress activities. The candidate must work collaboratively with cross‑functional counterparts in Clinical Development and Operations, Regulatory, Research, Finance, Legal, and Commercial as well as other ORIC functional groups to design and implement a medical strategy for rinzimetostat in prostate cancer and enozertinib in NSCLC.

• Build and lead the Global Medical Affairs (GMA) strategy and core capabilities in areas such as medical communications, operations, field medical, and a robust independent scientific research assessment process for all oncology assets.
• Align medical strategy with corporate objectives, clinical development, regulatory, and commercial imperatives.
• Build, mentor, and manage a high‑performing Medical Affairs team, including Field Medical Science Liaisons (MSLs), Medical Information, Publications, and Evidence Generation.
• Develop and execute the multi‑year US and global medical strategy and plan for rinzimetostat and enozertinib, including activities related to scientific engagement and communication, internal education, and patient advocacy.
• Work closely with the Clinical, Operations, CRO, and future MSL teams to provide recruitment, scientific, and engagement support to facilitate trial enrolment and conduct.
• Drive Key Opinion Leader (KOL) engagement, advisory boards, and relationships with academic institutions, patient advocacy groups, and medical societies.
• Lead integrated evidence planning, including clinical trial support, real‑world evidence, and investigator‑initiated studies.
• Partner with Clinical Development, Regulatory Affairs, Market Access, and Commercial teams to ensure alignment of medical and business objectives.
• Ensure all Medical Affairs activities comply with legal, regulatory, and corporate standards.
• Manage operating budget, systems, processes, and future personnel efficiently to maximize ORIC resources.

• An advanced medical/scientific degree: MD (preferred), PhD, or Pharm
  
  D with a strong background in oncology.
• Minimum 12–15+ years of experience in medical affairs, biotech and/or pharmaceutical industry with at least 5 years in a senior leadership role.
• Must have a strong scientific background in oncology with deep understanding of biomarker‑driven disease and ability to effectively analyze, synthesize, and communicate complex scientific information.
• Proven leadership experience and track record in oncology product launches, lifecycle management, and building Medical Affairs capabilities.
• Demonstrated ability to lead scientific engagement strategies and evidence generation programs and…